To understand the mechanisms of action of (R)-roscovitine and (S)-CR8, two related pharmacological inhibitors of cyclin-dependent kinases (CDKs), we applied a variety of '-omics' techniques to the human neuroblastoma SH-SY5Y and IMR32 cell lines: (1) kinase interaction assays, (2) affinity competition on immobilized broad-spectrum kinase inhibitors, (3) affinity chromatography on immobilized (R)-roscovitine and (S)-CR8, (4) whole genome transcriptomics analysis and specific quantitative PCR studies, (5) global quantitative proteomics approach and western blot analysis of selected proteins. Altogether, the results show that the major direct targets of these two molecules belong to the CDKs (1,2,5,7,9,12), DYRKs, CLKs and CK1s families. By inhibiting CDK7, CDK9 and CDK12, these inhibitors transiently reduce RNA polymerase 2 activity, which results in downregulation of a large set of genes. Global transcriptomics and proteomics analysis converge to a central role of MYC transcription factors downregulation. Indeed, CDK inhibitors trigger rapid and massive downregulation of MYCN expression in MYCN-amplified neuroblastoma cells as well as in nude mice xenografted IMR32 cells. Inhibition of casein kinase 1 may also contribute to the antitumoral activity of (R)-roscovitine and (S)-CR8. This dual mechanism of action may be crucial in the use of these kinase inhibitors for the treatment of MYC-dependent cancers, in particular neuroblastoma where MYCN amplification is a strong predictor factor for high-risk disease.
INTRODUCTION
Over 258 protein kinase inhibitors (low molecular weight compounds and antibodies) are currently in clinical trials, primarily against cancers: 116 are in phase I, 82 in phase II, 37 in phase III and 23 have reached the market. [1] [2] [3] [4] Although most were initially targeted against a specific protein kinase relevant to a specific disease, thorough selectivity studies show that kinase inhibitors target multiple kinases. [5] [6] [7] [8] This suggests that the mechanisms underlying their therapeutic effect are more likely due to a favorable combination of additive effects on different kinases rather than to a specific action on a unique kinase target. There is no strict correlation between target selectivity and therapeutic efficacy, advocating for the multi-target inhibitor pharmacologic approach, as illustrated by selectivity studies performed on marketed clinical kinase inhibitors. 6, 7, 9, 10 Among the 518 human kinases, cyclin-dependent kinases (CDKs) have received considerable attention because of their fundamental involvement in many physiological processes and in many diseases. 11 Consequently, a large variety of pharmacological inhibitors of CDKs have been identified, optimized and characterized (see reviews in references [12] [13] [14] [15] [16] [17] [18] .
Sixteen CDK inhibitors are currently in clinical trials. Among the first CDK inhibitors are the purines olomoucine, roscovitine, purvalanol and their analogues (reviews in Galons et al. 14 and Meijer and Raymond 19 ). The most recent analogues include (S)-CR8, [20] [21] [22] N-&-N1 23, 24 and others. [25] [26] [27] [28] (R)-roscovitine (CYC202 or Seliciclib) is currently in late phase 2 clinical trial against NSC lung cancer, breast and nasopharyngeal cancer. [29] [30] [31] [32] [33] Roscovitine is frequently used as a 'selective' inhibitor of CDKs in fundamental biological studies. Despite its initial identification as a CDK inhibitor and its rather good selectivity compared to many other kinase inhibitors also acting by competition with ATP binding at the catalytic site, roscovitine also binds other protein targets. 34, 35 CR8 was developed recently as a more potent, 'second generation' analogue of roscovitine ( Figure 1) . [20] [21] [22] Although it is slightly more potent (2-5 -fold) at inhibiting the kinase targets of roscovitine, it was found to be much more potent than roscovitine (50-100 -fold) at inducing apoptotic cell death in a variety of cell lines. 20, 21 This suggests that the direct targets of CR8 and roscovitine may differ, and that their mechanism of action might also be different.
To understand and compare the cellular effects of roscovitine and CR8, we used a variety of '-omics' approaches to examine the effects of these drugs on the human neuroblastoma SH-SY5Y and IMR32 cell lines, which were chosen as cellular models. Results show that both molecules have a complex pattern of primary targets, that they mostly downregulate the expression of key genes involved in cell cycle regulation, apoptosis, NFkB pathway and so on. Nevertheless, global analysis points towards a central role of c-MYC and MYCN downregulation in the action of these drugs. Both CDK inhibitors trigger rapid and massive downregulation of MYCN in MYCN-amplified neuroblastoma cell lines either in culture and when xenografted in nude mice. This data confirm and extend previous observations showing the links between CDKs and MYC, as well as the favorable effects of CDK inhibition on MYC-dependent cells, [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] suggesting that MYC dependence may constitute a selection criterion of cancer sub-groups for treatment by CDK inhibitors. This is of particular importance for neuroblastoma where MYCN amplification is invariably associated with poor prognosis (review in references [46] [47] [48] . In addition, roscovitine and CR8 inhibit CK1e, a target recently validated in overexpressed MYC context. 49 Figure S1) has been optimized as a secondgeneration derivative of roscovitine. [20] [21] [22] Although slightly more potent than roscovitine as an inhibitor of various kinase targets, CR8 was found to be much more potent than its parent molecule at inducing cell death in a variety of cells (average 71.2-fold higher potency on 6 cell lines in reference 20; average 58.5-fold higher potency on 9 neuroblastoma cell lines in reference 22) . To further explore the differences in their potency the two compounds were tested in the NCI 60 tumor cell lines panel. Results revealed an average 102, 31 and 15-fold higher potency of CR8 over roscovitine as measured by GI 50 , TGI and LC 50 , respectively (Table 1 ; Supplementary Figure S2) . No specific tumor type was found to display hyper-or hypo-sensitivity to CR8. In order to investigate and compare the intracellular mechanisms of action of both CDK inhibitors in detail, we selected the human neuroblastoma SH-SY5Y (non-amplified MYCN) and IMR32 (amplified MYCN) cell lines as representative tumor cell lines. To investigate the effects of CR8 on cell cycle progression we exposed IMR32 cells to 5 mM CR8 for 24 h and analyzed the cell cycle phase distribution by FACS. The expected, yet modest, increase in G2/M at the expense of G1 and S phase was observed ( Figure 1a) . We also ran cell synchronization experiments and compared the effects of CR8 on G1 (obtained by serum starvation), G2/M (obtained by nocodazole treatment) and asynchroneous, Log phase IMR32 cells. Figure 1a confirmed the expected synchronization and displays the effects of CR8. Dose-response curves showed that CR8 acts with equal potency at all cell cycle stages in terms of cell death induction (Figure 1b ).
RESULTS

CR8 is a potent cell death inducer derived from roscovitine CR8 (Supplementary
Interactomics study of roscovitine and CR8 Kinase interaction screen. The molecular targets of roscovitine have been quite extensively studied by various methods, including screening on various panels of purified kinases, 20, 29, 34, 35, 50 yeast three hybrid screens, 51 interaction assays 6 and affinity chromatography. 34 Various methods have shown that CR8 and roscovitine display an apparently similar specificity, with slightly enhanced activity of CR8 compared to roscovitine on CDKs (2-4-fold) and CK1 (7-10-fold). 20 To investigate and compare the molecular targets of roscovitine and CR8 using global approaches, we first made use of the DiscoveRx KinomeScan assay (402 kinases) 7 (Supplementary Figure S3 ; Table 2; Supplementary Table S1 ). Results show that the main targets of both compounds belong to the CK1 (casein kinase 1), CDK, CLK (cdc2 like kinase) and DYRK (dual specificity, tyrosine phosphorylation-regulated kinase) families of kinases (Table 2) . Interestingly, CK1e (CSNK1e) appeared as the first interaction target for both compounds among the 402 kinases.
Affinity chromatography. To evaluate the scope and nature of the direct targets of roscovitine and CR8, we used an affinity (Oumata et al., in preparation) . Each compound was immobilized on agarose beads through a linker. The position of the linker on the inhibitor was selected on the basis of the inhibitors' interactions and orientation in the CDK2 20, 34, 54 and CDK9 22 ATP-binding sites, as revealed by kinase/inhibitor co-crystal structures. Extracts of human neuroblastoma SH-SY5Y and IMR-32 cells were run on the immobilized inhibitors, the beads were extensively washed and the bound proteins were resolved by SDS-PAGE, followed by silver staining (Figures 2a and b) . Individual protein bands were cut from the stained gels, and proteins were identified following mass spectrometry of tryptic fragments. 34 Results are provided in Figures 2a and b (kinases) and in Supplementary Table S2 (all protein targets). Although many targets were common for both drugs in these two cell lines (and in other tissues and cell types not reported here), CR8 appeared to bind more proteins than roscovitine.
Competition affinity chromatography. A third approach was used to analyze the kinase targets of roscovitine and CR8. This method is based on an affinity matrix comprising a set of well-characterized broad-spectrum kinase inhibitors (KinAffinity developed by Evotec) to enrich the subproteome of endogenously expressed kinases of cells or tissues. Kinase inhibitors are screened against these matrixbound proteins to reveal the inhibitor's quantitative cellular kinase profile.
First, a lysate of SILAC-labeled SH-SY5Y cells was applied to KinAffinity beads adjusted to different concentrations. These quantitative binding experiments allow determining the concentration of the immobilized compounds required to obtain 50% binding of each target protein to the matrix (BC 50 ). Second, a lysate of SILAC-labeled SH-SY5Y cells was applied to 10-fold diluted KinAffinity beads in the presence of increasing concentrations of free roscovitine or CR8. These quantitative competition experiments determine the free compound concentration required for 50% target protein to remain bound to the matrix (CC 50 (Table 3) . Of these, 4 and 6 were protein targets specific to roscovitine and CR8, respectively, and 14 were shared by both drugs (Supplementary Tables S3B  and S3C ).
Whereas roscovitine displayed the highest affinities (five best Kd values) for PAK4, CDK7, CDK12 (CRK7), CDK9 and CK1d, CR8 displayed the highest affinity for CDK12, CDK9, MSK2, CK1d and CDK10. Furthermore, several other protein kinases involved in regulation of the cell cycle, cell proliferation, alternative splicing and neuronal functions (CK1e, CLK2, DYRK1A or CDK5) were also identified as roscovitine and CR8 targets. Other proteins detected on the matrix, such as cyclin T1, T2, K, H and B2, are likely to bind indirectly, through their CDK7, CDK9 and CDK1 partners. This is illustrated by the very similar Kd values of partner proteins (CDK7/ cyclin H/MAT1 or CDK9/cyclin T1). Finally, several phosphatidylinositol-5-phosphate 4 kinases were identified as CR8 targets. Roscovitine and CR8 were tested at a 10 mM concentration on a 402 kinases interaction panel. A semi-quantitative scoring of this primary screen was obtained. This score relates to a probability of a hit rather than strict affinity. Scores 410, between 1 to 10, and o1 indicate the probability of being a false positive is o20%, o10% and o5%, respectively. The 15 best scores are presented. Full results are available in the Supplementary Table S1 .
CDK/CK1 inhibitors and MYCN C Delehouze et al
The previously-identified roscovitine target pyridoxal kinase (PDXK) 35 is expressed in SH-SY5Y cells and bound to the KinAffinity matrix, yet it was not competed by roscovitine or CR8. This might be explained by the characteristic composition of the KinAffinity matrix, which exclusively contains broad-spectrum kinase inhibitors that bind their target kinases via the ATP-binding site. Since roscovitine is not directly binding at the PDXK ATP site, but at the pyridoxal site, displacement of PDXK from a matrix comprising Transcriptomics study of roscovitine and CR8 As a global approach to comparatively investigate the effects of roscovitine and CR8, we next performed a parallel transcriptomics study for both compounds. SH-SY5Y cells were exposed for 4 h to 50 mM roscovitine and 5 mM CR8 or the corresponding level of DMSO vehicle. mRNAs were extracted, purified and reversetranscribed, and the products were hybridized on 44 K Human Whole-Genome Agilent Technologies chips. The transcriptome was analyzed using the GeneSpring and DAVID software. Results show that, after 4 h, roscovitine and CR8 altered (X2-fold) the expression of 1523 and 1138 genes, respectively (Figure 3a) . Most altered genes were downregulated (1321 and 1037 for roscovitine and CR8, respectively) (Figure 3b) , although a few were upregulated (202 and 101, respectively) ( Figure 3c ). All downregulated and upregulated genes are listed in Supplementary  Tables S4 and S5 . An EASE analysis of these downregulated and upregulated genes is shown in Supplementary Tables S6 and S7, respectively. Table S8 shows downregulated genes which are direct roscovitine/CR8 targets, cell cycle, apoptosis or NFkB regulators. Genes showing a 410-fold downregulation, following exposure to roscovitine or CR8 are listed in Table 4 . To confirm the validity of this study, we verified the effects of the two drugs on the transcription of a selection of genes using straight PCR (Figure 3d ) or quantitative PCR (Figure 3e ): CDK7, GSG2 (haspin), c-MYC, p27 Kip1 , ING1, SIAH1, NEDD9 and actin or GAPDH as controls. Starting from the same number of cells, and measuring expression after a short exposure time, probably allows the use of housekeeping genes to normalize the data; this might not have been the case for longer exposure times and in situations where total expression of a large number of mRNAs is altered, and when higher levels of mRNAs might be present as seen in MYC overexpressing cells. 56 In our case, SH-SY5Y do not show overexpression of MYCN and thus mRNA quantification may reflect the reality. This might not have been the case with IMR32 cells which overexpress MYCN. Results confirmed those obtained in the Agilent global approach, notably the massive downregulation of c-MYC expression. The potential importance of the effects of the two compounds on Myc expression was highlighted by global analysis of the expression data, which showed a convergence on Myc (Supplementary Figure S4) . actin (71) GAPDH (87) c-MYC (86) p27 ( were amplified by PCR (28 cycles) and the reaction products were resolved by electrophoresis on agarose. Expression of actin and GAPDH mRNA was used as a reference. Ctrl, no mRNA. (e) Quantitative PCR was also performed with p27 Kip1 , CDK7, c-MYC, ING1, SIAH1 and NEDD9. Expression is displayed relative to vehicletreated cells and normalized according to actin or GAPDH expression.
CDK/CK1 inhibitors and MYCN C Delehouze et al exposed for 8 h to 50 mM roscovitine, 5 mM CR8, the corresponding level of DMSO vehicle or left untreated. Cells were pelleted and stored frozen until further processing. Proteins were extracted and subjected to trypsin proteolysis. The resulting tryptic peptides were then labeled with iTRAQ, and all samples were pooled prior to LC-MS analysis. A total of 18 193 peptides corresponding to 1320 proteins were identified and quantified (Figures 4a-c ; Supplementary Tables S9 and S10 ). Roscovitine triggered downregulation of substantially more proteins than CR8 (226 versus 41). Expression of 25 proteins was altered by both compounds. Cells were exposed for 4 h to either 50 mM roscovitine, 5 mM CR8 or corresponding amounts of DMSO. Proteins were extracted, trypsinized, iTRAQ labeled and samples mixed prior to mass spectrometry analysis. A total of 18 193 peptides corresponding to 1320 proteins were identified and quantified, of which 18.03% showed a 42-fold change in expression (a) by either one or both drugs. The level of these proteins was either downregulated (b) (182 proteins by roscovitine and 27 by CR8, of which 17 were downregulated by both) or upregulated (c) (44 proteins by roscovitine and 14 by CR8, of which 8 were upregulated by both). Numbers in parentheses represent the total number of proteins affected by roscovitine or CR8 treatment. The number of proteins displaying modified expression only in roscovitine treated cells, only in CR8 treated cells or by both treatments are shown in blue, red and black, respectively. Percentages indicate the proportion of these proteins relative to the total of proteins down-or upregulated by roscovitine or CR8 treatment. (d and e) Selected examples of downregulated proteins. Effects of dose (d) and time (e) of exposure to roscovitine or CR8 on the levels of GSG2 (haspin), c-MYC, p27
Kip1 and actin. Cells were exposed (d) to various concentrations of roscovitine or CR8 for 24 h or (e) for various times to 50 mM roscovitine, 5 mM CR8 or corresponding amounts of DMSO. Proteins were extracted, resolved by SDS-PAGE and analyzed by western blotting using appropriate antibodies.
Once again, global analysis of the protein expression data showed a convergence on MYC (Supplementary Figure S4) .
We next analyzed the effects of the two drugs on the levels of a selection of proteins (encoded by genes which showed downregulation in the transcriptomics study) by western blotting with appropriate antibodies (Figures 4d and e) . SH-SY5Y cells were exposed to various concentrations (Figure 4d ) or different durations (Figure 4e ) to roscovitine or CR8. Cells were extracted and proteins analyzed by SDS-PAGE and western blotting. Results confirmed dose-and time-dependent downregulation of proteins like c-MYC and p27 KIP1 , while a few proteins, like GSG2 (haspin), which showed downregulation at the mRNA level (Figures 4d and e) , did not show any significant downregulation at the protein level, illustrating the only partial coupling between mRNA and protein levels.
CDK inhibitors downregulate MYCN expression
Given that the data strongly support the conclusion that MYC is a downstream target of CDK inhibition, and the importance of MYC in the development of poor prognosis neuroblastoma, [46] [47] [48] we decided to focus our attention on the effects of CR8 on MYCN in neuroblastoma cells. MYCN is a rapid turnover protein as demonstrated by the use of MG132, a proteasome inhibitor, and cycloheximide, a global inhibitor of protein synthesis. Inhibition of proteasome leads to rapid accumulation of MYCN, while protein synthesis inhibition leads to rapid MYCN downregulation (Figure 5a ). Exposure to CR8 leads to a rapid (less than 6 h) downregulation of MYCN in IMR32 cells (Figure 5b ). We next tested the effects of CR8 on the stability of MYCN in nine different neuroblastoma cell lines (Figure 5c , but not by N6-methyl-CR8 and N6-methylroscovitine (the kinase inactive derivatives of CR8 and roscovitine, respectively). 35 Besides CDKs, roscovitine and CR8 interact with a few other kinases as shown above and earlier. 20, 34, 35 To examine whether interaction with any of these targets might account for the induction of MYCN downregulation by CDK inhibitors, we made use of a series of selective pharmacological inhibitors of these other kinases (none of these inhibit CDKs) ( Figure 6 ). IMR32 cells were exposed to various concentrations of pharmacological inhibitors of DYRK1A (Leucettine 41, 62, 63 ). In contrast to a general kinase inhibitor (staurosporine 68 ), none of these inhibitors induced downregulation of MYCN. Despite preferential interaction of roscovitine and CR8 with CK1, none of the reported CK1 inhibitors triggered MYCN downregulation. These results suggest that CR8 and roscovitine, and other CDK inhibitors, trigger MYCN downregulation through inhibition of CDKs rather than by interaction with secondary targets.
CR8 reduces IMR32 tumor growth and downregulates tumor MYCN in xenografts
We next tested the effects of CR8 on tumor growth and MYCN expression following IMR32 engraftment in immunocompromised mice (Figure 7 ). IMR32 xenografts were developed by (Figure 7b ), into the flank of NOD scid gamma mice. Once tumor growth was established, mice were randomly distributed in two groups and treated with either vehicle (DMSO/PEG300/water, 5/50/45) or CR8 (2 mg/ml in vehicle). Vehicle and drug were administered daily by intraperitoneal injection. Tumor growth was monitored regularly and tumor volumes, based on caliper measurements, were calculated as described in Grunwald et al. 69 Results clearly show that CR8 slows down tumor growth (Figure 7a and b) . When the CR8-resistant tumors were left out, tumor growth was clearly arrested and, in fact, tumor regression was observed (Figure 7b ). Figure 6 . Effect of different CDK and non-CDK inhibitors on MYCN levels. IMR32 were exposed for 10 h to 3 concentrations of CR8, roscovitine, MR4, N-&-N1, purvalanol A, SCH727965, AT7519, N6-methyl-CR8 and N6-methyl-roscovitine (kinase inactive derivatives of CR8 and roscovitine, respectively), SNS-032, flavopiridol, staurosporine (general kinase inhibitor), Leucettine L41 and harmine (DYRK1A inhibitors), TG003 (CLK1), IC261, DRF053 and D4476 (CK1), UO126 and PD098059 (MEK1). All drugs were tested at 5, 15 and 50 mM, except staurosporine (0.2, 0.6 and 2 mM). Cells were harvested and proteins were resolved by SDS-PAGE followed by western blotting with anti-MYCN antibodies. Actin was used as a loading control. To confirm the effect of CR8 on MYCN expression, tumors were collected at the end of the xenograft experiments, extracts were prepared and equal protein content samples were loaded on SDS-PAGE gels, followed by western blotting (Figure 7c ). Anti-actin antibodies confirmed roughly equal protein loading of all 20 samples. Anti-MYCN antibodies confirmed that all control tumors expressed high levels of MYCN. In contrast, most but not all CR8-treated tumors showed complete disappearance or at least massive downregulation of MYCN expression (Figure 7c ). Mcl-1 and CK1e were also downregulated as a result of exposure of mice to CR8 (data not shown), as expected from the effects of CDK inhibitors on Mcl-1 expression 22 and the correlation between MYCN overexpression and CK1e expression. 49 
DISCUSSION
In vitro targets of roscovitine and CR8 In this study, we have investigated in detail the selectivity of the kinase inhibitory purines roscovitine and CR8. Firstly, catalytic assays and interaction assays performed with recombinant protein kinases confirm and extend previously known data for roscovitine 6, 9, 20, 34, 50, 51 and CR8. 20 Both compounds show affinity for subclasses of CDKs, namely CDK1, 2, 3, 5, 7 and 9, but also DYRKs (1A, 1B), CLKs 1,2,4 and CK1s (e, g). Strikingly, CK1e appears to be one of the best targets of the two compounds.
Native targets of roscovitine and CR8 There are limitations associated with the use of recombinant kinases in selectivity assays: lack of natural post-translational modifications, lack of interacting partners, abnormal folding of an unknown proportion of the produced kinases, use of excess amounts of kinases, lack of competition between different targets, limitation to the cloned kinases and so on. Therefore, we investigated the native targets of roscovitine and CR8 in neuroblastoma cell lines using two affinity chromatography approaches ( Figure 2 , Table 3, Supplementary Tables S2 and S3) . These approaches provide a global view of potential targets (kinases/non-kinases) of roscovitine and CR8 from a given cell line/ tissue. Results confirm previously identified targets such as the above-mentioned CDKs, CK1s (CK1e in particular), CLKs, DYRKs and PDXK. They also point towards new potential targets such as PAK4, CDK10, CDK12 and associated cyclin K, [70] [71] [72] [73] [74] FADK1 and phosphatidylinositol-5-phosphate 4-kinases (CR8). Inhibition of the catalytic activity of these kinases has to be confirmed in vitro. Using the same competition affinity method with mouse brain or K562 leukemia cells extracts, we also identified PAK4, CDK7, CDK9, CDK12, DYRK1A, CK1d, CK1e and phosphatidylinositol-5-phosphate 4-kinases (CR8) as targets (unpublished) . A number of non-kinase proteins were found to bind to roscovitine-and CR8-beads (nonspecific binders, direct or indirect interactors or kinase substrates?).
Downstream targets of roscovitine and CR8
Investigating native targets from specific cell lines or tissues has limitations too: dependence on target expression, which varies in different cell lines or tissues, prevalence of the most abundantly expressed proteins, preponderance of soluble targets. It is likely that cellular responses to roscovitine and CR8 are the end result of a complex pattern of interactions with the targets identified in vitro.
In the context of anticancer activity towards c-MYC/MYCN-driven tumors, we believe that the main action of roscovitine and CR8 can be explained by a combined action on two sets of targets: the transcription regulating CDKs (CDK7/cyclin H/MAT1, CDK9/cyclin T and CDK12/cyclin K) and the closely related CK1d and CK1e.
CDK7, CDK9 and CDK12 regulate RNA polymerase II phosphorylation and activity. [70] [71] [72] [73] [74] [75] [76] [77] We therefore focused our work towards analysis of downstream targets, namely transcription and protein expression products. Global transcriptomics and proteomics approaches showed that the two kinase inhibitors inhibit transcription and protein expression, especially that of shortlived mRNAs and proteins, respectively, extending earlier results obtained with other cell lines. [78] [79] [80] One example is the cell survival factor Mcl-1, which is rapidly downregulated. 22 Another key example investigated here are members of the MYC transcription factors, and in particular MYCN. MYCN is frequently amplified in neuroblastoma [46] [47] [48] and this event, in association with ALK mutations, [81] [82] [83] [84] [85] is associated with poor prognosis. MYCN has a short-lived RNA and is a short-lived protein ( Figure 5 ). Here, we show that roscovitine and CR8 induce rapid and essentially complete downregulation of MYCN expression (Figures 5-7) . We believe that roscovitine and CR8, by inhibiting, even transiently, CDK7/cyclin H, CDK9/cyclin T and CDK12/cyclin K, reduce RNA polymerase II activity, leading to an arrest of MYCN synthesis under continued degradation conditions. This results in rapid clearance of the MYCN protein and downregulation of MYCN downstream targets. This fast and complete MYCN downregulation has been shown at the protein level in various neuroblastoma cell lines (Figures 5 and 6 ) as well as in tumors grown in animal models (Figure 7) . CDK2 inhibition has also been reported as synthetically lethal to MYCN. [37] [38] [39] 41, [43] [44] [45] One possibility is that CDK2 acts by phosphorylating and activating CDK9. 86 Another recently described mechanism is the CDK-mediated phosphorylation and activation of the SCF FBXO28 ubiquitin ligase, which promotes MYC-driven transcription and tumour development. 45 Besides the CDK inhibitors described here, two other types of drugs have been described to downregulate MYC/ MYCN: the Aurora kinase inhibitor CCT137690 87 --Aurora has been reported to stabilize MYCN 40 --and BET bromodomain inhibitors. 88, 89 These pharmacological treatments might be additive with CDK inhibitors.
Expression of CK1e correlates with MYCN amplification as well as c-MYC expression in neuroblastoma. 49 CK1e inhibition is synthetically lethal with c-MYC and MYCN. 49 Pharmacological inhibitor (IC261) and siRNAs of CK1e prevent growth of MYCNamplified xenografts. 49 CK1 inhibitors (IC261, DRF053 and D4476) clearly do not downregulate MYCN expression ( Figure 6 ). However, CR8 was found to downregulate the expression of CK1e (data not shown), suggesting that this effect could be downstream of MCYN downregulation. The fact that one of the main targets of roscovitine and CR8 is CK1e (and the related CK1d) suggests that this mechanism of action probably combines with CDK inhibition to generate antitumor activity of roscovitine and CR8 in MYCNamplified tumors.
Altogether these results suggest that roscovitine and CR8, and probably other related purine inhibitors, display anticancer activity thanks to a combination of two different and additive effects: inhibition of CDK2, CDK7, CDK9 and CDK12 and inhibition of CK1d/e. CDK inhibition but not CK1 inhibition leads to the downregulation of MYC and MCl-1. The molecular events downstream to CK1 inhibition remain to be identified. MYCN overexpressing tumors are particularly sensitive to these CDK/CK1 inhibitors that might be favorably combined with ALK inhibitors for the treatment of poor prognosis neuroblastoma. These results might be expanded to the most common malignant pediatric brain tumor, medulloblastoma, and other tumors where expression of MYC is also indicative of very poor prognosis.
MATERIALS AND METHODS
Drugs-reagents-antibodies-buffers-cell culture
Synthesis of roscovitine and CR8 without and with linker. Roscovitine and CR8 were synthesized as previously described. 21, 50 Compounds were stored as a dry powder, but diluted as 10 mM stock solution in dimethylsulfoxide (DMSO). Roscovitine beads were obtained as previously described. 34 CR8 þ linker was synthesized as described (Oumata et al., in preparation) and stored at À 20 1C at 100 mM in DMSO. Bead buffer. Constituents were 50 mM Tris A (pH 7.4), 5 mM sodium fluoride, 250 mM NaCl, 5 mM EDTA, 5 mM EGTA, 0.1% Nonidet P-40 and protease inhibitor cocktail.
Cell culture conditions. IMR32, LAN5 and LAN1 human cells (provided by Dr J. Bé nard, Villejuif) were grown in RPMI 1640 medium from Invitrogen (Cergy Pontoise, France) and SH-SY5Y human cells and the other neuroblastoma cell lines (provided by Dr J. Boix, Lleida and Dr J. Bé nard, Villejuif respectively, ) were grown in DMEM medium (Invitrogen). Medium were supplemented with 2 mM l-glutamine (Lonza, Verviers, Belgium), with antibiotics (penicillin-streptomycin) (Lonza) and 10% volume of fetal calf serum (Invitrogen). Cells were cultured at 37 1C with 5% CO 2 . Drug treatments were performed on exponentially growing cultures at the indicated concentrations and during indicated times. Control experiments were carried using appropriate dilutions of DMSO.
Interactomics-affinity chromatography assays
Kinase interaction panel (DiscovRx KinomeScan). Assays were performed essentially as reported previously 6, 7 and are described in detail in the Supplementary Material section.
Affinity chromatography on immobilized roscovitine and CR8. SH-SY5Y and IMR32 cells were cultured as described, extracted with bead buffer and extracts were loaded on CR8 and roscovitine sepharose beads as previously described 34 and described in more details in the Supplementary Material section.
Affinity competition assay (Evotec)-KinAffinity kinase target profiling. For SILAC, SH-SY5Y neuroblastoma cells were cultivated as described previously. 90, 91 In vitro association experiments were performed essentially as described in. 91, 92 KinAffinity beads (Evotec) representing a set of different broad-spectrum kinase inhibitors immobilized on Sepharose beads were applied for affinity chromatography. For competition experiments, SILAC-encoded cell extracts were added to 10-fold diluted KinAffinity beads and treated simultaneously with different concentrations of roscovitine or CR8. Identification and quantification are described in full in the Supplementary Material section.
Transcriptomics and proteomics
Transcriptomics and proteomics experiments were performed with SH-SY5Y cells using standard protocols described in detail in the Supplementary Material section.
Electrophoresis-western blotting
Following heat denaturation for 3 min, proteins were separated on a mini gel electrophoresis system (Invitrogen) using NuPage 10% Bis-Tris, 10 or 12 wells polyacrylamide gels. Electrophoresis and transfer were performed in XCell SureLock Mini-Cell system and XCell II Blot module from Invitrogen. The 0.45 mm nitrocellulose membrane was from Fisher Bioblock. These were blocked for 1 h with 5% low fat milk in tris-buffered saline-tween-20, incubated overnight at 4 1C (anti-actin (1:2000), c-Myc (1:1000), MYCN (1:50), SIAH1 (1:1000), Haspin (1:500) and p27 Kip1 (1:500)) and analyzed by Enhanced Chemiluminescence. The silver staining kit was purchased from GE Healthcare, Velizy-Villacoublay, France.
In vivo experiments
Cell lines, antibodies and reagents. IMR32 cells were maintained in RPMI 1640 supplemented with 10% FBS, 1% L-glutamine, and 0.1% gentamicin. Goat polyclonal anti-actin was obtained from Santa Cruz (sc-1615) and mouse monoclonal anti-MYCN from Calbiochem (OP13). CR8 was reconstituted in DMSO at a concentration of 40 mg/ml.
Xenografts. IMR32 cells were suspended in Matrigel (BD Worldwide, Le Pont de Claix Cedex, France, #354234) at a concentration of 100 000 cells/ml and kept on ice. NOD scid gamma (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice were injected subcutaneously with 100 ml of chilled Matrigel/cell slurry directly into the flank and allowed to establish for two weeks prior to drug delivery. Mice were administered, by intraperitoneal injection, 100 ml of either vehicle (DMSO/PEG300/ddH 2 O, 5/50/45) or CR8 (2 mg/ml), daily for up to 3 weeks. Tumor growth during the treatment was measured using digital calipers at indicated times using the formula: tumor volume ¼ (length Â width 2 )/2. 69 Mice were euthanized and tumors harvested either 1 day or 3 weeks post-treatment and frozen immediately on dry ice.
Immunoblotting. Tumor samples were minced using a clean razor blade and suspended in ACK buffer (0.15 M NH 4 Cl, 10 mM KHCO 3 and 0.1 mM EDTA) for 1 min on ice to lyse red blood cells. Tumors were subsequently washed with PBS and suspended in RIPA buffer (150 mM NaCl, 50 mM Tris pH 8.0, 0.5% sodium deoxycholate, 0.1% SDS and 1% NP-40) plus protease inhibitor (Roche, Boulogne-Billancourt Cedex, France, #14015000). Tumor samples were maintained in RIPA buffer for 5 min on ice and sonicated until the tumor dissolved. Protein concentration was determined using a protein assay dye reagent (BioRad, Marnes-la-coquette, France, #500-0006). Proteins (30 mg) were separated using SDS-PAGE in 10% polyacrylamide gels and transferred to PVDF membranes. ABBREVIATIONS BSA, bovine serum albumin; CDC2, cell division cycle 2; CDK, cyclin-dependent kinase; CHX, cycloheximide; CK1, casein kinase 1; CLK, cdc2-like kinase; CRKRS, cdc2-related protein kinase 7 (CDK12); DMEM, Dulbecco/Vogt modified Eagle's minimal essential medium; DMSO, dimethylsulfoxide; DTT, dithiothreitol; DYRK, dual specificity, tyrosine phosphorylation regulated kinase; FADK, focal adhesion kinase; FCS, fetal calf serum; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GSK-3, glycogen synthase kinase-3; PBS, phosphate-buffered saline; PDXK, pyridoxal kinase; RT, room temperature.
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